Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06343792 · ClinicalTrials.gov registry record · Phase 2
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
A Phase 2 study of Steroid Refractory GVHD, sponsored by ReAlta Life Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 11
- Study locations
NCT06343792 is a Phase 2 study of Steroid Refractory GVHD that is actively recruiting participants, run by ReAlta Life Sciences. The registered enrollment target is 66 participants. The trial reports 11 study locations across 6 states.
The verdict
NCT06343792, a Phase 2 study of Steroid Refractory GVHD, is actively recruiting participants, sponsored by ReAlta Life Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.
Conditions Studied
Interventions
- DRUG RLS-0071
Study Locations (11)
Other
- Site 3242 - Freiburg im Breisgau
- Site 3360 - Madrid
- Site 3227 - Salamanca
- Site 3101 - Seville
California
- Site 1091 - Duarte
- Site 1343 - Los Angeles
Ohio
- Site 1100 - Cincinnati
- Site 1382 - Columbus
Georgia
- Site 1318 - Atlanta
Missouri
- Site 1068 - St Louis
SE
- Site 3101 - Seville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2024-08-31 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06343792
The ClinicalTrials.gov registry entry for NCT06343792 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ReAlta Life Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Steroid Refractory GVHD appearing as the primary indexed condition, and to 1 intervention - of which RLS-0071 is the first listed.
NCT06343792 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT06343792 about?
NCT06343792 is a clinical study titled "Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease". This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-re...
What is the current status of trial NCT06343792?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-08-31. Estimated completion is 2026-12.
What conditions does trial NCT06343792 study?
This clinical trial studies the following conditions: Steroid Refractory GVHD.
What interventions are being tested in trial NCT06343792?
The interventions under investigation include: RLS-0071 (DRUG).
Who is sponsoring clinical trial NCT06343792?
This trial is sponsored by ReAlta Life Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06343792 being conducted?
This trial has 11 study locations across California, Georgia, Missouri, Ohio, SE. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.